Imunon | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.16, beating the estimate of USD -1.8052.

EBIT: As of FY2025 Q3, the actual value is USD -3.523 M.

Financial Metrics by Segment

Clinical Research

• OVATION 2 and MRD Trials: $212,000 for the nine months ended September 30, 2025, compared to $1,139,000 for the same period in 2024, a decrease of 81.4%.
• OVATION 3 Trial: $695,000 for the nine months ended September 30, 2025, with no comparable expense in 2024.
• PlaCCine Vaccine Phase 1 Trial: $42,000 for the nine months ended September 30, 2025, compared to $1,412,000 for the same period in 2024, a decrease of 97.0%.
• Other Clinical and Regulatory: $1,387,000 for the nine months ended September 30, 2025, compared to $1,900,000 for the same period in 2024, a decrease of 27.0%.
• Subtotal: $2,336,000 for the nine months ended September 30, 2025, compared to $4,451,000 for the same period in 2024, a decrease of 47.5%.

Non-Clinical R&D and CMC

• OVATION Program: $2,209,000 for the nine months ended September 30, 2025, compared to $851,000 for the same period in 2024, an increase of 159.6%.
• PlaCCine Vaccine Program: No expenses for the nine months ended September 30, 2025, compared to $2,554,000 for the same period in 2024.
• Manufacturing (CMC): $746,000 for the nine months ended September 30, 2025, compared to $1,551,000 for the same period in 2024, a decrease of 51.9%.
• Subtotal: $2,955,000 for the nine months ended September 30, 2025, compared to $4,956,000 for the same period in 2024, a decrease of 40.4%.

Total Research and Development Expenses

• $5,291,000 for the nine months ended September 30, 2025, compared to $9,407,000 for the same period in 2024, a decrease of 43.8%.

General and Administrative Expenses

• $5,098,000 for the nine months ended September 30, 2025, compared to $5,580,000 for the same period in 2024, a decrease of 8.6%.

Total Operating Expenses

• $10,389,000 for the nine months ended September 30, 2025, compared to $14,987,000 for the same period in 2024, a decrease of 30.7%.

Loss from Operations

• - $10,389,000 for the nine months ended September 30, 2025, compared to - $14,987,000 for the same period in 2024, a decrease of 30.7%.

Cash Flow

• Net Cash Used in Operating Activities: - $10,239,523 for the nine months ended September 30, 2025.
• Net Cash Used by Investing Activities: - $276,983 for the nine months ended September 30, 2025.
• Net Cash Provided by Financing Activities: $9,894,668 for the nine months ended September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue advancing its lead clinical program, IMNN-001, for the treatment of advanced ovarian cancer, and its COVID-19 booster vaccine, IMNN-101. The company is also focused on leveraging its non-viral DNA technology across its TheraPlas and PlaCCine modalities.
• Non-Core Business: The company is exploring potential partnerships and collaborations, as well as possible out-licensing opportunities for its drug candidates.
• Priority: The company aims to raise additional capital through public or private equity offerings, debt financing, and other strategic transactions to fund its operations and continue its research and development activities.